During the past decade, Crohn-Colitis Zentrum Bern Gemeinschaftspraxis Balsiger Seibold und Partner conducted 22 clinical trials. In the 10-year time frame, 22 clinical trials started and 6 clinical trials were completed, i.e. on average, 27.3% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 6 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Crohn-Colitis Zentrum Bern Gemeinschaftspraxis Balsiger Seibold und Partner" #1 sponsor was "Hoffmann-La Roche" with 4 trials, followed by "Celgene" with 3 trials sponsored, "Eli Lilly and Company" with 3 trials sponsored, "Galapagos NV" with 3 trials sponsored and "Janssen Research & Development, LLC" with 3 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Crohn-Colitis Zentrum Bern Gemeinschaftspraxis Balsiger Seibold und Partner" #1 collaborator was "Gilead Sciences" with 3 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator, "Galapagos NV" with 1 trials as a collaborator, "Swiss National Science Foundation" with 1 trials as a collaborator and "The Broad Foundation" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Crohn-Colitis Zentrum Bern Gemeinschaftspraxis Balsiger Seibold und Partner" are "Crohn's Disease" (9 trials), "Ulcerative Colitis" (7 trials), "Crohn Disease" (4 trials), "Colitis, Ulcerative" (2 trials) and "Crohn's Enteritis" (1 trials). Many other conditions were trialed in "Crohn-Colitis Zentrum Bern Gemeinschaftspraxis Balsiger Seibold und Partner" in a lesser frequency.

Most popular intervention types in "Crohn-Colitis Zentrum Bern Gemeinschaftspraxis Balsiger Seibold und Partner" are "Drug" (21 trials), "Biological" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Filgotinib" (4 trials), "Etrolizumab" (3 trials), "GED-0301" (3 trials) and "Guselkumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Crohn-Colitis Zentrum Bern Gemeinschaftspraxis Balsiger Seibold und Partner" are 22 trials for "All" genders.

Currently, there are NaN active trials in "Crohn-Colitis Zentrum Bern Gemeinschaftspraxis Balsiger Seibold und Partner". undefined are not yet recruiting, 5 are recruiting, 7 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 5 completed trials in Crohn-Colitis Zentrum Bern Gemeinschaftspraxis Balsiger Seibold und Partner, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Crohn-Colitis Zentrum Bern Gemeinschaftspraxis Balsiger Seibold und Partner, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".